Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Luke Mitcheson

Showing results (21-30 of 34) with videos related to

Pageof 4
Sort By:
Drug and Alcohol Dependence|June 27, 2016
DEVELOPMENT AND VALIDATION OF 'SURE': A PATIENT REPORTED OUTCOME MEASURE (PROM) FOR RECOVERY FROM DRUG AND ALCOHOL DEPENDENCEJoanne Neale, Silia Vitoratou, Emily Finch, et al.
Contemporary Clinical Trials|December 13, 2016
Effectiveness of adjunctive, personalised psychosocial intervention for non-response to opioid agonist treatment: Study protocol for a pragmatic randomised controlled trialJohn Marsden, Garry Stillwell, Jennifer Hellier, et al.
The Lancet. Psychiatry|June 16, 2023
Achieving integrated treatment: a realist synthesis of service models and systems for co-existing serious mental health and substance use conditionsJane Harris, Sonia Dalkin, Lisa Jones, et al.
Addiction (Abingdon, England)|July 1, 2026
Craving and personal functioning as mediators of extended-release buprenorphine efficacy: A four-way decomposition analysis from a randomised trialJohn Marsden, Mike Kelleher, Fiona Cowden, et al.
Addiction (Abingdon, England)|December 10, 2025
5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT) for alcohol use disorder: An open-label, phase 2, proof-of-concept, clinical trialJohn Marsden, Michael Kelleher, Fiona Dunbar, et al.
Health Technology Assessment (Winchester, England)|October 14, 2024
Care models for coexisting serious mental health and alcohol/drug conditions: the RECO realist evidence synthesis and case study evaluationElizabeth Hughes, Jane Harris, Tom Ainscough, et al.
Drug and Alcohol Dependence|April 16, 2014
Development of the Addiction Dimensions for Assessment and Personalised Treatment (ADAPT)John Marsden, Brian Eastwood, Robert Ali, et al.
Addiction (Abingdon, England)|June 20, 2025
Extended-release buprenorphine treatment for opioid use disorder: A mixed-methods study of response and experienceNatalie Lowry, Andrew McKechnie, Edward Day, et al.
Lancet (London, England)|April 15, 2014
Use of contingency management incentives to improve completion of hepatitis B vaccination in people undergoing treatment for heroin dependence: a cluster randomised trialTim Weaver, Nicola Metrebian, Jennifer Hellier, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|December 12, 2022
The Cost-Effectiveness of Financial Incentives to Achieve Heroin Abstinence in Individuals With Heroin Use Disorder Starting New Treatment Episodes: A Cluster Randomized Trial-Based Economic EvaluationJames Shearer, Nicola Metrebian, Tim Weaver, et al.
Pageof 4

Showing results (21-30 of 34) with videos related to

Sort By:
Pageof 4
Drug and Alcohol Dependence|June 27, 2016
DEVELOPMENT AND VALIDATION OF 'SURE': A PATIENT REPORTED OUTCOME MEASURE (PROM) FOR RECOVERY FROM DRUG AND ALCOHOL DEPENDENCEJoanne Neale, Silia Vitoratou, Emily Finch, et al.
Contemporary Clinical Trials|December 13, 2016
Effectiveness of adjunctive, personalised psychosocial intervention for non-response to opioid agonist treatment: Study protocol for a pragmatic randomised controlled trialJohn Marsden, Garry Stillwell, Jennifer Hellier, et al.
The Lancet. Psychiatry|June 16, 2023
Achieving integrated treatment: a realist synthesis of service models and systems for co-existing serious mental health and substance use conditionsJane Harris, Sonia Dalkin, Lisa Jones, et al.
Addiction (Abingdon, England)|July 1, 2026
Craving and personal functioning as mediators of extended-release buprenorphine efficacy: A four-way decomposition analysis from a randomised trialJohn Marsden, Mike Kelleher, Fiona Cowden, et al.
Addiction (Abingdon, England)|December 10, 2025
5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT) for alcohol use disorder: An open-label, phase 2, proof-of-concept, clinical trialJohn Marsden, Michael Kelleher, Fiona Dunbar, et al.
Health Technology Assessment (Winchester, England)|October 14, 2024
Care models for coexisting serious mental health and alcohol/drug conditions: the RECO realist evidence synthesis and case study evaluationElizabeth Hughes, Jane Harris, Tom Ainscough, et al.
Drug and Alcohol Dependence|April 16, 2014
Development of the Addiction Dimensions for Assessment and Personalised Treatment (ADAPT)John Marsden, Brian Eastwood, Robert Ali, et al.
Addiction (Abingdon, England)|June 20, 2025
Extended-release buprenorphine treatment for opioid use disorder: A mixed-methods study of response and experienceNatalie Lowry, Andrew McKechnie, Edward Day, et al.
Lancet (London, England)|April 15, 2014
Use of contingency management incentives to improve completion of hepatitis B vaccination in people undergoing treatment for heroin dependence: a cluster randomised trialTim Weaver, Nicola Metrebian, Jennifer Hellier, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|December 12, 2022
The Cost-Effectiveness of Financial Incentives to Achieve Heroin Abstinence in Individuals With Heroin Use Disorder Starting New Treatment Episodes: A Cluster Randomized Trial-Based Economic EvaluationJames Shearer, Nicola Metrebian, Tim Weaver, et al.
Pageof 4